DRG Epidemiology's coverage of progressive supranuclear palsy (PSP) comprises epidemiological estimates of diagnosed prevalence across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of PSP for each country, as well as annualized case counts projected to the national population.
The diagnosed prevalence of PSP is forecast over a period of 20 years for the major mature pharmaceutical markets.
DRG Epidemiology's PSP forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PSP over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts the following PSP patient population:
Diagnosed Prevalence of Progressive Supranuclear Palsy per 100,000 People of All Ages in 2021 and 2041
Relative Sizes of the Factors Contributing to the Trend in Diagnosed Prevalent Cases of Progressive Supranuclear Palsy over the Next 20 Yearsttttttttt
Epidemiology Data
Methods
Diagnosed Prevalent Cases
Reference Materials
Literature Review
Studies Included in the Analysis of Progressive Supranuclear Palsy
Studies Excluded from the Analysis of Progressive Supranuclear Palsy
Risk/Protective Factors
Risk/Protective Factors for Progressive Supranuclear Palsy
Bibliography
Abbreviations
Glossary
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
Alison Isherwood, M.Sc., M.Res., Ph.D.
Alison Isherwood, M.Sc., M.Res., Ph.D., is a senior director on the Epidemiology team at Clarivate. She specializes in female cancers, biomarker, and infectious disease epidemiology, particularly involving the impact of vaccination. She holds a B.Sc. in medical microbiology, a master’s degree in research in the life sciences (specializing in virology and parasitology), and an M.Sc. in epidemiology, all from the University of Edinburgh. She also holds a Ph.D. in molecular virology from the University of Reading in England.
